Avenacy intros generic Compazine

Avenacy has launched prochlorperazine edisylate injection, which is a generic of GlaxoSmithKline’s Compazine. Prochlorperazine edisylate injection is indicated to control severe nausea and vomiting and for the treatment of schizophrenia. Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.

Avenacy's prochlorperazine edisylate injection, is available in 10 mg/2 ml (5 mg per ml) 10-pack multi-dose vials. In line with Avenacy’s mission to champion patient safety and streamline patient care, prochlorperazine edisylate injection will feature the company’s highly differentiated packaging and labeling to support accurate medication selection, the company said.

[Read more: Avenacy debuts generic Cyklokapron]

Avenacy will begin shipping prochlorperazine edisylate injection to wholesale partners this week. The company said it is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards.

Prochlorperazine edisylate injection had a market value of approximately $15 million for the 12 months ending in June 2023, per IQVIA.

[Read more: Generic sterile injectables market to reach $196.2B by 2029]